Selecta Biosciences Inc (NASDAQ:SELB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm currently has a $15.00 target price on the stock. Zacks Investment Research’s target price indicates a potential upside of 13.21% from the company’s current price.

According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “

Other equities analysts have also recently issued research reports about the company. Canaccord Genuity began coverage on Selecta Biosciences in a research report on Monday, July 18th. They set a “buy” rating and a $20.00 price objective for the company. Needham & Company LLC began coverage on Selecta Biosciences in a research report on Monday, July 18th. They set a “buy” rating and a $28.00 price objective for the company. Finally, Stifel Nicolaus began coverage on Selecta Biosciences in a research report on Monday, July 18th. They set a “buy” rating and a $23.00 price objective for the company.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/selecta-biosciences-inc-selb-upgraded-by-zacks-investment-research-to-buy-2.html

Shares of Selecta Biosciences (NASDAQ:SELB) traded up 1.30% during mid-day trading on Tuesday, reaching $13.25. The company’s stock had a trading volume of 21,107 shares. The company has a 50 day moving average of $12.37 and a 200-day moving average of $12.89. Selecta Biosciences has a 12 month low of $10.26 and a 12 month high of $16.32.

In other news, major shareholder Nanodimension Management Ltd purchased 385,000 shares of the stock in a transaction that occurred on Monday, June 27th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $5,390,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Amir Nashat purchased 150,000 shares of the stock in a transaction that occurred on Monday, June 27th. The shares were purchased at an average price of $14.00 per share, for a total transaction of $2,100,000.00. The disclosure for this purchase can be found here.

Several large investors have recently added to or reduced their stakes in SELB. Polaris Venture Management Co. V L.L.C. bought a new position in shares of Selecta Biosciences during the second quarter worth about $26,919,000. Perceptive Advisors LLC bought a new position in shares of Selecta Biosciences during the second quarter worth about $6,296,000. JPMorgan Chase & Co. bought a new position in shares of Selecta Biosciences during the second quarter worth about $4,215,000. FMR LLC bought a new position in shares of Selecta Biosciences during the second quarter worth about $3,997,000. Finally, Vanguard Group Inc. bought a new position in shares of Selecta Biosciences during the second quarter worth about $1,679,000.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.

5 Day Chart for NASDAQ:SELB

Get a free copy of the Zacks research report on Selecta Biosciences (SELB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Selecta Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.